Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 2
Submit an article Journal homepage
119
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Bendamustine Mitoxantrone and Rituximab (BMR): A New Effective Regimen for Refractory or Relapsed Indolent Lymphomas

Rudolf Weide Haematology/Oncology Group Practice, Nevers Straβe 5, 56068 Koblenz, Germany
,
Jochen Heymanns Haematology/Oncology Group Practice, Nevers Straβe 5, 56068 Koblenz, Germany
,
Annette Gores Haematology/Oncology Group Practice, Nevers Straβe 5, 56068 Koblenz, Germany
&
Hubert Köppler Haematology/Oncology Group Practice, Nevers Straβe 5, 56068 Koblenz, Germany
Pages 327-331 | Published online: 01 Jul 2009

  • The French Cooperative Group on chronic lymphocytic leukemia (1990) "Effects of chlorambucil and the therapeutic decision in initiai forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients". Blood 75, 1414-1421.
  • Horning, S.J. and Rosenberg, S.A. (1984) 'The natural history of initially untreated low-grade non-Hodgkin's lymphomas", N. Engl. J Med.311. 1471-1475.
  • Coiffier, B., Thieblemont. C., Felman, P., Salles, G. and Berger, F. (1999) "Indolent non-follicular lymphomas: characteristics, treatment and outcome", Semin. Hematol. 336, 198- 208.
  • Johnson, P.W., Rohatiner, A.Z., Whelan. J.S., et al. (1995) "Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center", J. Clin. Oncol. 13. 140-147.
  • Reff, M.E., Carner. K., Chambers. K.S., et al. (1994) "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood 83, 435-445.
  • McLaughlin. P., Cabanillas, F., Grillo-Lopez. A.J., et al. (1996) "IDEC-C2B8 anti-CD20 antibody final report on a phase II pivotal trial in patients with relapsed low grade or follicular lymphoma". Blood88, 90a, abstract, Suppl. I.
  • Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., et al (1999) "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy", J Clin. Oncol. 17, 268-276.
  • Ozegowski, W. and Krebs, D. (1971) "IMET 3393. gamma-l-Methyl-5-bis-(ß-chloräthyl)-amino-benzimidazoIyI(2))-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste", Zbl Pharm. 110. 1013-1019.
  • Anger, G., Hesse. P. Kühler. P. and Baufeld, H. (1967) "Erste klinische Erfahrungen mit einem neuen Zytostatikum". Deutsch Gesundheitswes 22. 1079-1084.
  • Ruffert, K., Jahn. H., Syrbe, G., Stauch. M., Jorke, D. and Kühn, R. (1989) "Cytostasan (Bendamustin) in der Alternativtherapie maligner Non-Hodgkin-Lymphome". Z Klin Med. 44, 671-674.
  • Anger, G., Fink, R., Fleischer, J., et al. (1975) "Vergleichsuntcrsuchungen zwischen Cylostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem Bronchialkarzinom", Deutsch Gesundheitswes 30, 1280-1285.
  • Bremer, K. and Roth, W. (1996) "Bendamustine. a low toxic nitrogen-mustard derivative with high efficacy in malignant tymphomas", Tumordiagn. u. Ther. 17, 1-6.
  • Hiddemann, W., Unterhalt, M., Buske. C. and Sack. H. (1997) "Treatment of follicular follicle center lymphomas: current status and future perspectives", J. Intern. Med. 740. 55-62. suppl.
  • McLaughlin, P., Hagemeister, F.B., Romaguera, J.E., et al. (1996) "Fludarabine. mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma", J. Clin. Oncol. 14, 1262-1268.
  • Cheson, B.D., Horning, S.J., Coiffier, B.,et al. (1999) "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", J. Clin. Oncol. 17. 1244-1253.
  • Cheson. B.D, Bennett, J.M., Rai. K.R., et al (1988) "Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Recommendations of the NCI-Sponsored Working Group", Am. J. Hematol. 29, 152-163.
  • Giraldo, P., Pelegrin, F. and Palomera, L. (2000) "Relapsed follicular lymphoma. Response to fludarabine-mitoxantrone regimen and monoclonal anti CD20 (rituximab)", Blood 96, Part I. abstract 3157.
  • Kaminski, M.S., Estes. J., Zasadny, K.R., et al. (2000) "Radioimmunotherapy with iodine(131)I tositumomab for chemotherapy-relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow up of the University of Michigan experience", Blood 96, 1259-1266.
  • Witzig, T.E., White, C.A., Wiseman, G.A., et al. (1999) "Phase I/II trial of IDEC- Y2B8 radioimmunotheraphy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma". J Clin. Oncol. 17, 3793-3803.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.